Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1

Canadian Journal of Microbiology

Volumn 57, Issue 3, 2011, Pages 256-261

  Romeu, Belkis ^a   González, Elyzabeth ^a   del Campo, Judith ^a   Acevedo, Reynaldo ^a   Zayas, Caridad ^a   Valdés, Yolanda ^a   Cabrera, Osmir ^a   Cuello, Maribel ^a   Balboa, Julio ^a   Lastre, Miriam ^a   Pérez, Oliver ^a  

^a FINLAY INSTITUTE   (Cuba)

Author keywords

Adjuvant; Cochleate; Nasal immunization; Tetanus toxoid

Indexed keywords

ADJUVANT; ADJUVANT FINLAY COCHLEATE 1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODY FORMATION; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; PROTEOLIPIDS; SALIVA; TETANUS TOXOID; VAGINA;

MUS; NEISSERIA MENINGITIDIS;

EID: 79952209563     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/W11-002     Document Type: Note

References (24)

1. Bracho, G., Zayas, C., Wang, L., Coppel, R., Pérez, O., and Petrovsky, N. 2009. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malar. J. 8: 35. doi:10.1186/1475-2875-8-35. PMID:19250541.
2. Chen, K., and Cerutti, A. 2010. Vaccination strategies to promote mucosal antibody responses. Immunity, 33(4): 479-491. doi:10. 1016/j.immuni.2010.09.013. PMID:21029959.
3. Czerkinsky, C., Anjueie, F., McGhee, J.R., Geoige-Chundy, A., Holmgren, J., Kieny, M.-P., et al. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170(1): 197-222. doi:10.1111/j.1600-065X.1999.tb01339.x. PMID: 10566152.
4. del Campo, J., Zayas, C., Romeu, B., Acevedo, R., González, E., Bracho, G., et al. 2009. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses. Methods, 49(4): 301-308. doi:10.1016/j.ymeth.2009.03.025. PMID: 19410000.
5. del Campo, J., Lindqvist, M., Cuello, M., Bäckström, M., Cabrerra, O., Persson, J., et al. 2010. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine, 28(5): 1193-1200. doi:10.1016/j.vaccine.2009. 11.035. PMID:19945418.
6. Donovan, M.D., Flynn, G.L., and Amidon, G.L. 1990. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7(8): 863-868. doi:10.1023/A:1015921101465. PMID:2235883.
7. Haneberg, B., Dalseg, R., Wedege, E., Høiby, E.A., Haugen, I.L., Oftung, F., et al. 1998. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66(4): 1334-1341. PMID:9529050.
8. Harandi, A.M., and Medaglini, D. 2010. Mucosal Adjuvants. Curr. HIV Res. 8(4): 330-335. doi:10.2174/157016210791208695. PMID:20353395.
9. Hatzifoti, C., Bacon, A., Marriott, H., Laing, P., and Heath, A.W. 2008. Liposomal co-entrapment of CD40mAb induces enhanced IgG responses against bacterial polysaccharide and protein. PLoS ONE, 3(6): e2368. doi:10.1371/journal.pone.0002368. PMID:18523585.
10. Holmgren, J., Czerkinsky, C., Lycke, N., and Svennerholm, A.M. 1992. Mucosal immunity: implications for vaccine development. Immunobiology, 184(2-3): 157-179. PMID:1587541.
11. Isaka, M., Yasuda, Y., Kozuka, S., Miura, Y., Taniguchi, T., Matano, K., et al. 1998. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine, 16(17): 1620-1626. doi:10.1016/ S0264-410X(98)00066-8. PMID:9713937.
12. Kang, S.-M., and Compans, R.W. 2003. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J. Virol. 77(6): 3615-3623. doi:10.1128/JVI.77.6. 3615-3623.2003. PMID:12610137.
13. Lindblad, E.B. 2004. Aluminium adjuvants -in retrospect and prospect. Vaccine, 22(27-28): 3658-3668. doi:10.1016/j.vaccine. 2004.03.032. PMID:15315845.
14. Mann, J.F.S., Scales, H., Shakir, E., Alexander, J., Carter, K., Mullen, A., and Ferro, V. 2006. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods, 38(2): 90-95. doi:10.1016/j.ymeth.2005.11.002. PMID:16414269.
15. Mbow, M.L., De Gregorio, E., Valiante, N.M., and Rappuoli, R. 2010. New adjuvants for human vaccines. Curr. Opin. Immunol. 22(3): 411-416. doi:10.1016/j.coi.2010.04.004. PMID:20466528.
16. Men, Y., Thomasin, C., Merkle, H.P., Gander, B., and Corradin, G. 1995. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine, 13(7): 683-689. doi:10.1016/0264-410X(94)00046-P. PMID: 7668038.
17. Neutra, M.R., and Kozlowski, P.A. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2): 148-158. doi:10.1038/nri1777. PMID:16491139.
18. Pérez, O., Bracho, G., Lastre, M., Mora, N., del Campo, J., Gil, D., et al. 2004. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol. Cell Biol. 82(6): 603-610. doi:10.1111/j.1440-1711.2004.01293.x. PMID: 15550118.
19. Pérez, O., Lastre, M., Cabrera, O., del Campo, J., Bracho, G., Cuello, M., et al. 2007. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand. J. Immunol. 66(2-3): 271-277. doi:10.1111/j.1365-3083.2007.01981.x. PMID:17635804.
20. Qi, B., Narita, T., Sugiya, H., and Murakami, M. 2009. Pilocarpine-induced salivary fluid secretion in the perfused submandibular gland of the rat. J. Med. Invest. 56(Suppl.): 281-283. doi:10.2152/jmi.56.281. PMID:20224203.
21. Rodríguez, T., Pérez, O., Ménager, N., Ugrinovic, S., Bracho, G., and Mastroeni, P. 2005. Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery. Vaccine, 23(10): 1312-1321. doi:10.1016/j.vaccine. 2004.07.049. PMID:15652674.
22. Schipper, N.G., Verhoef, J.C., and Merkus, F.W. 1991. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm. Res. 8(7): 807-814. doi:10.1023/A:1015830907632. PMID: 1924131.
23. Sierra, G.V., Campa, H.C., Varcacel, N.M., Garcia, I.L., Izquierdo, P.L., Sotolongo, P.F., et al. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2): 195-207, discussion 208-210. PMID:1812432.
24. Tafaghodi, M., Jaafari, M.-R., and Tabassi, S.A.S. 2006. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur. J. Pharm. Biopharm. 64(2): 138-145. doi:10.1016/j.ejpb.2006.05.005. PMID:16797952.